{"disease":{"id":"optic-nerve-glioma","name":"optic nerve glioma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04648462","title":"Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Maastricht Radiation Oncology","has_results":false},{"nct_id":"NCT05278715","title":"Modified CV Regimen in Optic Pathway Glioma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Beijing Sanbo Brain Hospital","has_results":false},{"nct_id":"NCT03326388","title":"Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Great Ormond Street Hospital for Children NHS Foundation Trust","has_results":false},{"nct_id":"NCT02839720","title":"Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}